The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Melatonin in Alzheimer's disease and other neurodegenerative disorders
Open accessAbstract
Increased oxidative stress and mitochondrial dysfunction have been identified as common pathophysiological phenomena associated with neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD). As the age-related decline in the production of melatonin may contribute to increased levels of oxidative stress in the elderly, the role of this neuroprotective agent is attracting increasing attention. Melatonin has multiple actions as a regulator of antioxidant and prooxidant enzymes, radical scavenger and antagonist of mitochondrial radical formation. The ability of melatonin and its kynuramine metabolites to interact directly with the electron transport chain by increasing the electron flow and reducing electron leakage are unique features by which melatonin is able to increase the survival of neurons under enhanced oxidative stress. Moreover, antifibrillogenic actions have been demonstrated in vitro, also in the presence of profibrillogenic apoE4 or apoE3, and in vivo, in a transgenic mouse model. Amyloid-β toxicity is antagonized by melatonin and one of its kynuramine metabolites. Cytoskeletal disorganization and protein hyperphosphorylation, as induced in several cell-line models, have been attenuated by melatonin, effects comprising stress kinase downregulation and extending to neurotrophin expression. Various experimental models of AD, PD and HD indicate the usefulness of melatonin in antagonizing disease progression and/or mitigating some of the symptoms. Melatonin secretion has been found to be altered in AD and PD. Attempts to compensate for age- and disease-dependent melatonin deficiency have shown that administration of this compound can improve sleep efficiency in AD and PD and, to some extent, cognitive function in AD patients. Exogenous melatonin has also been reported to alleviate behavioral symptoms such as sundowning. Taken together, these findings suggest that melatonin, its analogues and kynuric metabolites may have potential value in prevention and treatment of AD and other neurodegenerative disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metals, Toxicity and Oxidative Stress
Valko, M., Morris, H., & Cronin, M. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867053764635 · Cited by 5,018
Neurodegenerative diseases and oxidative stress
Barnham, K. J., Masters, C. L., & Bush, A. I. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1330 · Cited by 3,683
Superoxide radical and superoxide dismutases
Fridovich, I. (1995) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.64.070195.000525 · Cited by 3,455
Hydrogen peroxide mediates amyloid β protein toxicity
Behl, C. (1994) · Cell · doi:10.1016/0092-8674(94)90131-7 · Cited by 2,074
Reppert, S. M., Weaver, D. R., & Ebisawa, T. (1994) · Neuron · doi:10.1016/0896-6273(94)90055-8 · Cited by 1,096
Hensley, K., Carney, J. M., Mattson, M. P., Aksenova, M., Harris, M., Wu, J. F., Floyd, R. A., & Butterfield, D. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3270 · Cited by 1,086
Mitochondria, oxygen free radicals, disease and ageing
Raha, S., & Robinson, B. H. (2000) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)01674-1 · Cited by 1,066
Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease
Mecocci, P., MacGarvey, U., & Beal, M. F. (1994) · Annals of Neurology · doi:10.1002/ana.410360510 · Cited by 1,037
Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines
Panov, A. V., Gutekunst, C.-A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., & Greenamyre, J. T. (2002) · Nature Neuroscience · doi:10.1038/nn884 · Cited by 1,030
The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927
Oxidative stress in Alzheimer’s disease
Smith, M. A., Rottkamp, C. A., Nunomura, A., Raina, A. K., & Perry, G. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00040-5 · Cited by 895
Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases
Selkoe, D. J. (2004) · Nature Cell Biology · doi:10.1038/ncb1104-1054 · Cited by 863
Alam, Z. I., Jenner, A., Daniel, S. E., Lees, A. J., Cairns, N., Marsden, C. D., Jenner, P., & Halliwell, B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031196.x · Cited by 845
Mitochondrial Dysfunction in Neurodegenerative Diseases
Johri, A., & Beal, M. F. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.192138 · Cited by 806
Hensley, K., Hall, N., Subramaniam, R., Cole, P., Harris, M., Aksenov, M., Aksenova, M., Gabbita, S. P., Wu, J. F., Carney, J. M., et al. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65052146.x · Cited by 779
Kitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N., & LaFerla, F. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2868-05.2005 · Cited by 697
Mark, R. J., Pang, Z., Geddes, J. W., Uchida, K., & Mattson, M. P. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-03-01046.1997 · Cited by 551
Autopsy Samples of Alzheimer's Cortex Show Increased Peroxidation In Vitro
Subbarao, K. V., Richardson, J. S., & Ang, L. C. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb08858.x · Cited by 463
Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension
Scheer, F. A. J. L., Van Montfrans, G. A., van Someren, E. J. W., Mairuhu, G., & Buijs, R. M. (2004) · Hypertension · doi:10.1161/01.hyp.0000113293.15186.3b · Cited by 451
Antioxidant Vitamin Intake and Risk of Alzheimer Disease
Luchsinger, J. A., Tang, M.-X., Shea, S., & Mayeux, R. (2003) · Archives of Neurology · doi:10.1001/archneur.60.2.203 · Cited by 414
Melatonin Prevents Death of Neuroblastoma Cells Exposed to the Alzheimer Amyloid Peptide
Pappolla, M. A., Sos, M., Omar, R. A., Bick, R. J., Hickson-Bick, D. L. M., Reiter, R. J., Efthimiopoulos, S., & Robakis, N. K. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-05-01683.1997 · Cited by 359
Weldon, D. T., Rogers, S. D., Ghilardi, J. R., Finke, M. P., Cleary, J. P., O’Hare, E., Esler, W. P., Maggio, J. E., & Mantyh, P. W. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-06-02161.1998 · Cited by 348
Neuroendocrine rhythms and sleep in aging men
van Coevorden, A., Mockel, J., Laurent, E., Kerkhofs, M., L'Hermite-Baleriaux, M., Decoster, C., Neve, P., & Van Cauter, E. (1991) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1991.260.4.e651 · Cited by 336
Matsubara, E., Bryant‐Thomas, T., Pacheco Quinto, J., Henry, T. L., Poeggeler, B., Herbert, D., Cruz‐Sanchez, F., Chyan, Y., Smith, M. A., Perry, G., et al. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01654.x · Cited by 332
Liu, R.-Y., Zhou, J.-N., van Heerikhuize, J., Hofman, M. A., & Swaab, D. F. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.1.5394 · Cited by 304
Fischer, A., Sananbenesi, F., Pang, P. T., Lu, B., & Tsai, L.-H. (2005) · Neuron · doi:10.1016/j.neuron.2005.10.033 · Cited by 277
Cybrids in Alzheimer's disease: a cellular model of the disease?
Swerdlow, R. H., Parks, J. K., Cassarino, D. S., Maguire, D. J., Maguire, R. S., Bennett, J. P., Davis, R. E., & Parker, W. D. (1997) · Neurology · doi:10.1212/wnl.49.4.918 · Cited by 272
Do plasma melatonin concentrations decline with age?
Zeitzer, J. M., Daniels, J. E., Duffy, J. F., Klerman, E. B., Shanahan, T. L., Dijk, D.-J., & Czeisler, C. A. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00266-1 · Cited by 239
Laurin, D. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh124 · Cited by 231
Melatonin mediates two distinct responses in vascular smooth muscle
Doolen, S., Krause, D. N., Dubocovich, M. L., & Duckles, S. P. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00064-8 · Cited by 229
Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease
de la Monte, S. M., Luong, T., Neely, T. R., Robinson, D., & Wands, J. R. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780140 · Cited by 227
Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles
Hilditch-Maguire, P. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.19.2789 · Cited by 226
Behan, W. M. H., McDonald, M., Darlington, L. G., & Stone, T. W. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702940 · Cited by 225
Functional mitochondria are required for amyloid β‐mediated neurotoxicity
Cardoso, S. M., Santos, S., Swerdlow, R. H., & Oliveira, C. R. (2001) · The FASEB Journal · doi:10.1096/fj.00-0561fje · Cited by 203
Gitto, E., Tan, D.-X., Reiter, R. J., Karbownik, M., Manchester, L. C., Cuzzocrea, S., Fulia, F., & Barberi, I. (2001) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357011777747 · Cited by 196
F4 ‐ Isoprostanes as Specific Marker of Docosahexaenoic Acid Peroxidation in Alzheimer's Disease
Nourooz‐Zadeh, J., Liu, E. H. C., Yhlen, B., Änggåard, E. E., & Halliwell, B. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720734.x · Cited by 187
Melatonin, circadian rhythms, and sleep
Arendt, J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010123431510 · Cited by 179
Yamadera, H., Ito, T., Suzuki, H., Asayama, K., Ito, R., & Endo, S. (2000) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2000.00711.x · Cited by 148
Daily rhythm of serum melatonin in patients with dementia of the degenerate type
Uchida, K., Okamoto, N., Ohara, K., & Morita, Y. (1996) · Brain Research · doi:10.1016/0006-8993(96)00086-8 · Cited by 138
Effect of Cytochrome c on the Generation and Elimination of O2⨪ and H2O2 in Mitochondria
Zhao, Y., Wang, Z.-B., & Xu, J.-X. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209681200 · Cited by 129
Onyango, I. G., Bennett, J. P., & Tuttle, J. B. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.01.026 · Cited by 56
Cited by
Melatonin—A pleiotropic, orchestrating regulator molecule
Hardeland, R., Cardinali, D. P., Srinivasan, V., Spence, D. W., Brown, G. M., & Pandi-Perumal, S. R. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.12.004 · Cited by 843
Self-citationPhysiological effects of melatonin: Role of melatonin receptors and signal transduction pathways
PANDIPERUMAL, S., TRAKHT, I., SRINIVASAN, V, SPENCE, D., MAESTRONI, G., ZISAPEL, N., & CARDINALI, D. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.04.001 · Cited by 791
Self-citationMitochondrial Oxidative Stress—A Causative Factor and Therapeutic Target in Many Diseases
Kowalczyk, P., Sulejczak, D., Kleczkowska, P., Bukowska-Ośko, I., Kucia, M., Popiel, M., Wietrak, E., Kramkowski, K., Wrzosek, K., & Kaczyńska, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413384 · Cited by 495
Revisiting the cholinergic hypothesis in the development of Alzheimer's disease
Craig, L. A., Hong, N. S., & McDonald, R. J. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.03.001 · Cited by 486
Melatonin and inflammation-Story of a double-edged blade
Hardeland, R. (2018) · Journal of Pineal Research · doi:10.1111/jpi.12525 · Cited by 455
Self-citation
Metadata
- Authors
- Srinivasan, V, Pandi-Perumal, Sr., Cardinali, D., Poeggeler, B., & Hardeland, R.
- Venue
- Behavioral and Brain Functions
- Published
- 2006-05-04
- Volume
- 2
- Issue
- 1
- Pages
- 15-15
- ISSN
- 1744-9081 (ISSN-L)
- OpenAlex
- W2114181374
- Cited by
- 223
- References
- 41
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.